Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409593 | 0.89 | CYP3A4 (0.59) | LSSKDM4ECYP3A4CYP2D6 | |
| SCHEMBL13391092 | 0.89 | LSS (0.58) | LSSTHRBAKR1C3 | |
| SCHEMBL13391090 | 0.81 | LSS (0.50) | LSSTHRBAKR1C3TACR3KDM4E | |
| SCHEMBL27759916 | 0.79 | KDM4E (0.62) | LSSAKR1C3KDM4ECYP3A4CYP2D6 | |
| SCHEMBL14456755 | 0.79 | CYP3A4 (0.65) | LSSKDM4ECYP3A4CYP2D6 | |
| SCHEMBL13391389 | 0.78 | TACR3 (0.53) | TACR3KDM4EACKR3 | |
| SCHEMBL13391205 | 0.77 | CYP3A4 (0.61) | KDM4ECYP3A4CYP2D6 | |
| SCHEMBL14355927 | 0.77 | LSS (0.46) | LSSTHRBAKR1C3TACR3KDM4E | |
| SCHEMBL13409072 | 0.77 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL13409046 | 0.75 | ALDH1A1 (0.48) | KDM4ECYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | LSS 3221/4885THRB 1200/4885AKR1C3 3299/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | LSS 1975/4885THRB 3729/4885AKR1C3 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.